Drugs / Amphotericin B Lipid emulsion
Amphotericin B Lipid emulsion
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT00876824 | Jul 2009 → Jan 2011 | visceral leishmaniasis | Bharat Serums and Vaccines Limited | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Amphotericin B Lipid emulsion | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00876824 ↗ |
| Known as | ABLE | “single infusion of preformed amphotericin B (AmB) lipid emulsion (ABLE) in comparison with that of liposomal formulation (LAmB).” PMID 25233346 ↗ Sep 2014 |
| Known as | Amphomul | “Amphotericin B lipid emulsion (Amphomul) 15 mg/kg on day 1 in group A for treatment of Visceral Leishmaniasis” NCT00876824 ↗ |